Márquez-Escobar Verónica Araceli, Alonso-Cerda María José, Rosales-Mendoza Sergio, Betancourt-Mendiola María de Lourdes
Biotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, Av. Sierra Leona 550, Lomas de San Luis, San Luis Potosí 78210, Mexico.
Recombinant Biopharmaceuticals Laboratory, School of Chemical Sciences, Autonomous University of San Luis Potosí, Manuel Nava 6, Av. Dr. Manuel Nava, San Luis Potosí 78210, Mexico.
Vaccines (Basel). 2025 Jan 28;13(2):139. doi: 10.3390/vaccines13020139.
BACKGROUND/OBJECTIVES: Nanovaccines have significant potential to enhance immunization strategies by improving efficacy, safety, and cost-effectiveness. In particular, organic nanoparticles hold promise for the generation of low-cost nanovaccines obtained by environmentally friendly methods. In this study, the feasibility of using zein nanoparticles (NPs) as carriers for an antigenic peptide (p30) and the receptor binding domain (RBD) from SARS-CoV-2 spike protein was explored.
A synthesis method for zein NPs was established by combining previously reported techniques, and the resulting NPs were characterized in terms of morphology, particle size, polydispersity index (PDI), surface charge, and colloidal stability using dynamic light scattering (DLS) and transmission electron microscopy (TEM). Tween 20 was employed as a surfactant to enhance particle stability and prevent aggregation.
The zein NPs were deemed safe based on an in vitro cytotoxicity assay using Vero cells. Immunogenicity assessments demonstrated that zein NPs:p30 and zein NPs:RBD induced IgG responses in test mice, whose magnitude was comparable to those achieved with alum as an adjuvant.
These findings support the use of zein NPs as promising vaccine delivery vehicles with adjuvant effects due to their ease and environmentally friendly synthesis, high stability, and low cost.
背景/目的:纳米疫苗在提高免疫策略的有效性、安全性和成本效益方面具有巨大潜力。特别是,有机纳米颗粒有望通过环保方法生产低成本纳米疫苗。在本研究中,探索了使用玉米醇溶蛋白纳米颗粒(NPs)作为抗原肽(p30)和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD)载体的可行性。
结合先前报道的技术建立了玉米醇溶蛋白NPs的合成方法,并使用动态光散射(DLS)和透射电子显微镜(TEM)对所得NPs的形态、粒径、多分散指数(PDI)、表面电荷和胶体稳定性进行了表征。使用吐温20作为表面活性剂来提高颗粒稳定性并防止聚集。
基于使用Vero细胞的体外细胞毒性试验,玉米醇溶蛋白NPs被认为是安全的。免疫原性评估表明,玉米醇溶蛋白NPs:p30和玉米醇溶蛋白NPs:RBD在试验小鼠中诱导了IgG反应,其强度与使用明矾作为佐剂时相当。
这些发现支持将玉米醇溶蛋白NPs用作有前景的疫苗递送载体,因其合成简便、环保、稳定性高且成本低而具有佐剂效应。